Skip to main content
. 2024 Mar 11;13(5):1223–1237. doi: 10.1007/s40123-024-00919-w

Fig. 2.

Fig. 2

Symptoms and ocular surface outcomes within control (home-based therapy) and treatment (MBE-IPL-MGX) groups at 2-month follow-up. a Ocular surface disease index questionnaire (OSDI); b symptom assessment in dry Eye questionnaire (SANDE) and c ocular surface staining (OSS). *P < 0.05, ***P < 0.001